With the upcoming collaboration (announced in November) of ZEN-3694 with Pfizer, I thought I would write a little blurb to make sure we have the dots connected. The phase 1b/2 trial of ZEN-3694 combined with Pfizer’s Talazoparib (breast cancer) is slated to begin in Q1/19 so hopefully soon and is to test safety and efficacy of the combination. ZEN-3694 has already shown good symmetry with Enzalutamide which is Pfizer’s prostate cancer drug. Drugs like Enzalutamide and Janssen’s Abiraterone lose their effectiveness quite quickly and ZEN-3694 picks up there and extends the treatment. Therein possibly lies Pfizer’s interest in ZEN-3694. This is just one person's musings but is it possible that Pfizer and Zenith were in discussions over ZEN-3694 and Zenith put it on hold pending this trial as success with a breast cancer combo also would drive up the value of ZEN-3694 to Pfizer. Zenith could be wanting these results to decide on a value. This might be what caused this collaboration to happen to be able to decide on a value to both sides. This might also explain why the rumoured Zenith or ZEN-3694 sale last year never happened and this surfaced in lieu. Just a thought! Hopefully, we will get more information on the trial this week and have an idea how long this trial is expected to run.